THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today announced the expansion of its intellectual property portfolio. Opexa’s intellectual property portfolio has grown to reach 98 issued and validated patents worldwide. Additionally, Opexa is expanding its IP protection to cover B-cell mediated diseases in connection with its recently announced development program in Neuromyelitis Optica.
Opexa recently received a Notice of Allowance for Canadian patent No. 2,459,969, entitled, “Autologous T-Cell Vaccines Materials and Methods,” which broadly covers the Company’s core T-cell technology platform for the development of patient-specific immunotherapies. Once issued, this will bring the number of granted and validated patents (U.S. and international) in the Company’s IP portfolio to 98, including in-licensed patents. This group of patents mainly covers T-cell mediated autoimmune diseases, including multiple sclerosis.
Help employers find you! Check out all the jobs and post your resume.
